1.
Effects of an antimitotic drug on mechanical behaviours of the cytoskeleton in distinct grades of colon cancer cells
by Seyedpour, S.M
Journal of biomechanics, 2014, Vol.48 (6), p.1172-1178
2.
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, ph...
by DiNardo, Courtney D
The lancet oncology, 2018, Vol.19 (2), p.216-228
3.
Differential Determinants of Cancer Cell Insensitivity to Antimitotic Drugs Discriminated by a One-Step Cell Imaging Assay
by Tang, Yangzhong
Journal of biomolecular screening, 2013, Vol.18 (9), p.1062-1071
4.
The anti-mitotic drug griseofulvin induces apoptosis of human germ cell tumor cells through a connexin 43-dependent molecular mechanism
by Mauro, V
Apoptosis (London), 2013, Vol.18 (4), p.480-491
5.
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in...
by Pagel, John M
The lancet oncology, 2022, Vol.23 (8), p.1021
6.
Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis
by Mantelli, F
British Journal of Ophthalmology, 2007, Vol.91 (12), p.1656-1661
7.
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
by Zhu, Andrew X
The lancet oncology, 2018, Vol.19 (7), p.940-952
8.
Rethinking production of Taxol.sup.[R] using endophyte biotechnology
by Kusari, Souvik
Trends in biotechnology (Regular ed.), 2014, Vol.32 (6), p.304
9.
The microbiome, cancer, and cancer therapy
by Helmink, Beth A
Nature medicine, 2019, Vol.25 (3), p.377-388
10.
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
by Bruix, Jordi, Dr
The Lancet (British edition), 2016, Vol.389 (10064), p.56-66
11.
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
by Souers, Andrew J
Nature medicine, 2013, Vol.19 (2), p.202-208
12.
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, pha...
by Loibl, Sibylle
The lancet oncology, 2018, Vol.19 (4), p.497-509
13.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
by Rittmeyer, Achim, MD
The Lancet (British edition), 2016, Vol.389 (10066), p.255-265
14.
Corrigendum: PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin
by Bajou, Khalid
Nature medicine, 2015, Vol.21 (5), p.537-537
15.
Correction to: The protein kinase C[beta]-selective inhibitor, enzastaurin, attenuates amphetamine-stimulated locomotor activity and self-administration behaviors in rats
by Altshuler, Rachel D
Psychopharmacology, 2019, Vol.236 (11), p.3243
16.
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
by Langer, Corey J, Dr Prof
The lancet oncology, 2016, Vol.17 (11), p.1497-1508
17.
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
by Loi, Sherene
The lancet oncology, 2019, Vol.20 (3), p.371-382
18.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
by Balar, Arjun V, Dr
The Lancet (British edition), 2016, Vol.389 (10064), p.67-76
19.
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
by Fehrenbacher, Louis, Dr
The Lancet (British edition), 2016, Vol.387 (10030), p.1837-1846
20.
A Case Series of Eight Patients with Clinical Anaphylaxis in the Setting of Vincristine Administration
by Hill, David A., MD, PhD
Journal of allergy and clinical immunology, 2016, Vol.139 (2), p.AB40-AB40
